Provectus Biopharma (PVCT) CEO converts 320,890 shares from note

Rhea-AI Filing Summary

PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing exercised derivative securities to acquire additional common stock. An 8% unsecured convertible promissory note converted into 32,089 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per preferred share, then those preferred shares converted into 320,890 shares of common stock. Following these conversions, Pershing directly holds 2,847,849 shares of common stock. These were non‑market derivative conversions, not open‑market purchases or sales.

Insights

Equity capital markets analyst

PVCT's CEO increased direct equity exposure through derivative conversions, not market buying or selling.

CEO Edward Pershing converted an 8% unsecured convertible promissory note into 32,089 shares of Series D-1 Convertible Preferred Stock at $2.862 per preferred share, then converted those preferred shares into 320,890 common shares. This is reported as a derivative exercise/conversion, not an open-market trade.

The filing shows 2,847,849 common shares directly owned after the transactions, with no remaining related derivative position listed. The economic signal is moderate: Pershing increased his common equity holdings but did so via previously agreed financing terms rather than discretionary market purchases or sales.

Insider Trade Summary

32,089 shares exercised/converted

Mixed 2 txns

Insider Pershing Edward

Role CEO

Type	Security	Shares	Price	Value
Exercise	8% Unsecured Convertible Promissory Note	0	$0.00	--
Exercise	Series D-1 Convertible Preferred Stock	32,089	$0.00	--

Holdings After Transaction: 8% Unsecured Convertible Promissory Note — 0 shares (Direct, null); Series D-1 Convertible Preferred Stock — 2,847,849 shares (Direct, null)

Footnotes (1)

1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing. On May 23, 2026, the 2025 Note was converted into 32,089 shares of Series D-1 Preferred Stock.

Key Figures

Preferred shares issued: 32,089 shares Common shares from conversion: 320,890 shares Conversion price per preferred share: $2.862 +2 more

5 metrics

Preferred shares issued 32,089 shares Series D-1 Convertible Preferred Stock from note conversion on May 23, 2026

Common shares from conversion 320,890 shares Common Stock received upon conversion of Series D-1 Preferred

Conversion price per preferred share $2.862 8% unsecured convertible promissory note into Series D-1 Preferred

Post-transaction common holdings 2,847,849 shares Common Stock directly owned by Edward Pershing after transactions

Conversion ratio 10 common per preferred Each Series D-1 Preferred share convertible into 10 common shares

Key Terms

Series D-1 Convertible Preferred Stock, 8% Unsecured Convertible Promissory Note, automatic conversion, Certificate of Designation, +1 more

5 terms

Series D-1 Convertible Preferred Stock financial

"Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock"

8% Unsecured Convertible Promissory Note financial

"The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note"

automatic conversion financial

"The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock"

Certificate of Designation regulatory

"in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock"

A certificate of designation is a formal document that spells out the specific rights and rules attached to a particular class or series of stock, usually preferred shares. Think of it as a rulebook or menu that lists dividend terms, liquidation priority, conversion or redemption rights and any special voting protections; investors use it to judge how much income, control or downside protection those shares will provide compared with other securities.

2025 Financing financial

"The 2025 Note was issued pursuant to the Issuer's 2025 Financing"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pershing Edward

(Last) (First) (Middle)

800 S. GAY STREET,

SUITE 1610

(Street)

KNOXVILLE TENNESSEE 37929

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PROVECTUS BIOPHARMACEUTICALS, INC. [ PVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
8% Unsecured Convertible Promissory Note	$2.862	05/23/2026		M			$85,000	05/23/2025	05/23/2026	Series D-1 Convertible Preferred Stock(3)(4)	32,089	$0	$870,000	D
Series D-1 Convertible Preferred Stock	(1)	05/23/2026		M		32,089		05/23/2026	(2)	Common Stock	320,890	$0	2,847,849	D

Explanation of Responses:

1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").

2. The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

3. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing.

4. On May 23, 2026, the 2025 Note was converted into 32,089 shares of Series D-1 Preferred Stock.

	/s/ Edward Pershing	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PVCT CEO Edward Pershing report on this Form 4?

Edward Pershing reported exercising derivative securities to acquire common stock. An 8% unsecured convertible promissory note converted into Series D-1 Convertible Preferred Stock, which then converted into common shares, increasing his direct ownership without any open-market purchases or sales.

How many Provectus Biopharmaceuticals (PVCT) shares did the CEO acquire?

The CEO effectively acquired 320,890 shares of common stock. First, 32,089 Series D-1 Convertible Preferred shares were issued, then each preferred share converted into 10 common shares, resulting in 320,890 common shares credited to his direct holdings.

What was the conversion price for the 8% unsecured convertible promissory note at PVCT?

The outstanding principal and interest of the 8% unsecured convertible promissory note converted into Series D-1 Convertible Preferred Stock at $2.862 per preferred share. This price governed how many preferred shares were issued before those shares converted into common stock.

How many Provectus Biopharmaceuticals (PVCT) shares does the CEO own after these transactions?

After the conversions, Edward Pershing directly owns 2,847,849 shares of common stock. This total reflects the newly issued 320,890 common shares from converted preferred stock added to his prior holdings as reported in the Form 4.

Were the PVCT CEO’s transactions open-market buys or sells of common stock?

The transactions were not open-market buys or sells. They are reported as derivative exercises/conversions: a convertible promissory note converted into preferred stock, and that preferred stock then converted into common stock, all at specified terms rather than market prices.